Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Lupus Erythematosus, DiscoidLupus Erythematosus, Systemic
Interventions
DRUG

R932333

R393233 6% (60 mg/g), bid

DRUG

Placebo

Placebo, bid

Trial Locations (15)

10032

Columbia University Medical Center, New York

11042

North Shore Long Island Health System, Lake Success

19104

University of Pennsylvania-Dermatology Research Office, Philadelphia

23507

Virginia Clinical Research, Inc, Norfolk

27104

Wake Forest University Health Sciences, Winston-Salem

46601

Memorial Medical Group Clinical Research Institute, South Bend

73104

Oklahoma Medical Research Foundation, Oklahoma City

75231

Metroplex Clinical Research Center, Dallas

77030

University of Texas Medical School at Houston, Houston

84132

University of Utah Department of Dermatology, Salt Lake City

90027

Wallace Rheumatic Study Center, Los Angeles

94063

Stanford Dermatology, Redwood City

V5Z 4E8

University of British Columbia, Vancouver Dermatology Clinical Trials Unit, Vancouver

R3C 1R4

Dermadvances Research, Winnipeg

L3P 1A8

Lynderm Research, Inc, Markham

Sponsors
All Listed Sponsors
lead

Rigel Pharmaceuticals

INDUSTRY